Triple-Negative Breast Cancer (TNBC) Completed Phase 1 Trials for Irinotecan (DB00762)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT000316817-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)Treatment